Chapter

Anti-HIV agents to be used in drug combination regimens

07/2011; DOI:10.1007/978-3-0348-7869-2_1 pp.1-23

ABSTRACT Antiviral therapy and, particularly, anti-HIV therapy has definitely come of age [1]. There are now more than 30 compounds that have been formally approved for the therapy of virus infections. The nucleoside
reverse transcriptase inhibitors (NRTIs) zidovudine, didanosine, zalcitabine, stavudine, lamivudine and abacavir are used
in the treatment of human immunodeficiency virus (HIV) infections and lamivudine is also licensed for the treatment of hepatitis
B virus (HBV) infections. The nucleotide reverse transcriptase inhibitor (NtRTI) tenofovir has been approved for the treatment
of HIV infections and is also effective againstHBVinfections. The non-nucleoside reverse transcriptase inhibitors (NNRTIs) nevirapine, delavirdine and efavirenz are exclusively
used in the treatment of HIV infections, and so are the HIV protease inhibitors (PIs) saquinavir, ritonavir, indinavir, nelfinavir,
amprenavir and lopinavir.

0 0
 · 
0 Bookmarks
 · 
36 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

30 compounds
 
amprenavir
 
anti-HIV therapy
 
Antiviral therapy
 
didanosine
 
effective againstHBVinfections
 
HBV
 
HIV
 
HIV infections
 
HIV protease inhibitors
 
human immunodeficiency virus
 
indinavir
 
lamivudine
 
lopinavir
 
non-nucleoside reverse transcriptase inhibitors
 
nucleotide reverse transcriptase inhibitor
 
ritonavir
 
stavudine